Sign In
Buy MKGAF
$149.28
-7.84 (-4.99%)
At Close: Jun 22, 2026
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
01:50pm, Saturday, 03'rd Aug 2024
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene
Merck KGaA: The Drop Makes The Upside All The Sweeter
03:39am, Thursday, 04'th Jul 2024
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark
Merck KGaA shares slump on neck cancer trial failure
11:20am, Tuesday, 25'th Jun 2024
Merck KGaA shares fell by as much as 10% after the company announced the termination of its phase III trial of xevinapant in neck cancer. The interim analysis revealed that the study is unlikely to m
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
04:34pm, Monday, 24'th Jun 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
01:06pm, Wednesday, 29'th May 2024
Merck KGaA (MKGAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
09:50am, Wednesday, 29'th May 2024
Merck KGaA (MKGAF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
05:00pm, Thursday, 23'rd May 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American
Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
12:31pm, Wednesday, 15'th May 2024
Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Ma
Merck KGaA's Q1 adjusted profit declines less than feared
01:30am, Wednesday, 15'th May 2024
Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.
We are expecting life sciences to be stronger in the second half of 2024, says Merck KGaA CEO
12:30pm, Thursday, 07'th Mar 2024
Belén Garijo, CEO of Merck KGaA, discusses full-year results and her outlook for the life sciences industry.
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
12:02pm, Thursday, 07'th Mar 2024
Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO M
Merck KGaA forecasts return to organic earnings growth in 2024
01:09am, Thursday, 07'th Mar 2024
Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs
'Europe is lagging behind' on innovation: Merck KGaA CEO
10:15am, Thursday, 18'th Jan 2024
Belén Garijo, CEO of science and technology company Merck KGaA, discusses European regulation, growth and innovation with CNBC at Davos.
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.
07:43am, Tuesday, 16'th Jan 2024
Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.
Merck KGaA's experimental MS drug fails in late stage trials sending shares tumbling
11:25am, Wednesday, 06'th Dec 2023
Merck KGaA shares plunged more than 12% on Wednesday after the company announced that its experimental multiple sclerosis (MS) drug evobrutinib failed to meet the primary endpoint in Phase 3 clinical
